This retrospective study documents the prevalence of various histopathological diagnoses within a practice specializing in veterinary dentistry and oral surgery. Histopathology results obtained from biopsies of oral lesions from 403 dogs and 73 cats were sorted and categorized. Lesions of inflammatory origin represented the most common histopathology result in cats (n ¼ 37; 51%), followed by squamous cell carcinoma (n ¼ 27; 37%). The most common histopathological diagnoses in dogs were malignant neoplasms (n ¼ 151; 37%), followed by tumors of odontogenic origin (n ¼ 138, 34%) and lesions of inflammatory origin (n ¼ 114; 28%). The results of this study are representative of a private referral dentistry practice and are compared to other studies that assessed common oral neoplasia diagnoses in dogs and cats. Treatment options and prognoses of the most common canine and feline neoplasms are discussed.
Introduction
Multiple studies exist assessing the prevalence of oral tumors in dogs and cats. To the author's knowledge, no studies have looked at prevalence within a private veterinary specialty practice limited to dentistry only. To determine and verify the most common oral pathologies encountered in a private referral dentistry practice, the results of histopathology samples obtained from the oral cavity of dogs and cats were compiled and categorized. A discussion of the most prevalent tumors and current treatment options follows.
Materials and Methods
Histopathology samples from a private referral dentistry and oral surgery practice (Arizona Veterinary Dental Specialists) were retrospectively documented. Biopsies of 73 cats and 403 dogs between 2010 and 2015 were submitted for histopathology, and the results were reviewed and categorized. The rationale for submission of histopathology in each case was a gross abnormality noted during conscious or anesthetized oral examination.
Results

Cats
Of the feline histopathology results reviewed, 29 were from spayed females, 1 from an intact female, and 43 from castrated males. Ages ranged from 1 to 20 years, with a mean of 9.4 years and a median of 10 years. The predominant breed was domestic short hair (n ¼ 44; 60.3%), followed by domestic long hair (n ¼ 8; 11%). The remainder was a blend of pure breeds, including Siamese (n ¼ 5; 7%), Ragdoll (n ¼ 5; 7%), Maine coon (n ¼ 4; 5%), Persian (n ¼ 3; 4%), and Himalayan (n ¼ 2; 3%).
In cats, 51% (n ¼ 37) of histopathology samples were of an inflammatory origin. Two (3%) feline histopathological diagnoses were odontogenic tumors. One case was a peripheral odontogenic fibroma (POF), and one was an ameloblastic fibro-odontoma.
Based on histological results, malignant neoplasms comprised the diagnosis in 34 (47%) cases. The most common malignancy reported was oral squamous cell carcinoma (SCC), which was diagnosed 27 (37%) times. One case of fibrosarcoma (FS) and 1 case of malignant melanoma (MM) were also diagnosed (Table 1) .
Dogs
Of 403 canine samples, 202 were from female patients (194 spayed and 8 intact females). Of the 201 samples from male dogs, 193 were castrated and 8 were intact. The mean age of the dogs was 9.3 years, with a median of 10 years and a range of 0.4 to 20 years.
The predominant breed of dog represented was mixed, with 73 cases (18%). Labrador retrievers were the most common purebred (n ¼ 34; 8%), followed by golden retrievers (n ¼ 23; 5.7%). The mean weight was 21.4 kg, and the median and range were 19.5 and 1.8 to 88 kg, respectively. Dogs of the 403 histopathology results reviewed, 28% (N ¼ 115) of the canine tissue samples were determined to be inflammatory in origin. Odontogenic tumors represented 34% (N ¼ 139) of the total cases. Malignant neoplasia was diagnosed in 30% (N ¼ 122) of the tissue samples examined (Tables 2, 3 and 4) .
Discussion
The results of our feline retrospective study are similar to other studies. The University of California-Davis Dentistry and Oral Surgery Service (UC) analyzed 107 biopsy samples of cats from 1995 to 2001. 1 This study reported a 53% (n ¼ 57) occurrence of biopsy specimens as being of an inflammatory nature, compared to 51% (n ¼ 37) in this study (AZ). Odontogenic tumors represented 3% (UC/AZ, n ¼ 3/2) of the reported feline results in both studies. Malignant neoplasms were reported at 32% (n ¼ 34) in the UC study versus 47% (n ¼ 34) in the present study. Both studies reported SCC as the most common oral malignant neoplasm in cats, with the present study reporting a 37% (n ¼ 27) occurrence rate and UC reporting 19% (n ¼ 20) in the samples tested.
The UC study reported histopathology results of 363 samples collected from dogs from 1995 to 2001. 1 There was little difference in frequency of reported inflammatory samples between the UC study and the AZ study, 25% (n ¼ 89) and 28% (n ¼ 114), respectively. The incidence of odontogenic tumors in dogs was different in the present study (n ¼ 138; 34%) compared to the UC study (n ¼ 44; 13%). One possible reason for this difference is that peripheral fibromas and peripheral ossifying fibromas were categorized as hyperplasias rather than odontogenic tumors in the UC study (Table 5) . Canine acanthomatous ameloblastomas (CAAs) were common odontogenic tumors, with UC reporting 10% (n ¼ 39) and AZ reporting 14% (n ¼ 55%) of all histopathology samples diagnosed as CAA.
Regarding malignant neoplasms in dogs, UC reported that MM was the most common diagnosis at 7% (n ¼ 26). In contrast, the AZ study reported that SCC was the most commonly diagnosed oral malignant neoplasm in dogs at 7% (n ¼ 28). The current study saw MM with a prevalence of 4% (n ¼ 18).
A weakness of the current study exists in that a second pathologist did not review the original diagnoses. Misdiagnosis of the original diagnosis could exist, thereby skewing results. In addition, multiple pathologists provided the diagnoses discussed in the current study. The utilization of different pathologists could lead to inconsistency of diagnoses and different results.
Feline Oral SCC
This study reported that 37% (n ¼ 27) of all feline oral biopsies were diagnosed as SCC. Interestingly, oral SCCs in cats and people share many similarities. Feline SCC is the most common feline oral tumor, usually affecting older cats, 2 and is also the most frequently encountered oral tumor in people. 3 Both cats and humans are prone to developing SCC in the regions of the floor of the mouth and tongue.
2,4-6 Both human oral SCC and feline oral SCC tend to be resistant to chemotherapy and prove difficult to completely excise with sufficient margins. 7 Due to these commonalities, feline SCC is often used as a model for human head and neck oral SCC. [7] [8] [9] [10] [11] Despite recent advances, the long-term prognosis for cats with SCC is generally poor if clean surgical margins cannot be obtained. One study of 54 cats with SCC that received minimal treatment (antibiotics and/or nonsteroidal anti-inflammatory drugs) had a median survival time of 44 days after presentation and 33 days after biopsy, and the 1-year survival rate was 9.5%. 12 Metastasis occurred in the mandibular lymph nodes in 36% of feline SCC cases in 1 study. 13 However, clinical signs of metastasis are not traditionally observed, since local aggressiveness of the primary tumor usually results in euthanasia or death of the patient before signs of metastasis are observed.
14 Even with the current use of multimodal therapies, cure rates are extremely low. Survival times are significantly extended only related to small lesions that can be completely excised and are followed by postsurgical radiation therapy. 15 Large nonresectable tumors have a very poor prognosis.
Several factors, such as exposure to flea collars and eating canned food or tuna, have been shown to increase the risk of SCC. 16 Exposure to secondhand cigarette smoke showed a statistically insignificant 2-fold increase in risk of oral SCC development. 16 Although the human papilloma virus has been associated with human head and neck SCC and has been implicated in feline oral SCC, more investigation is needed to confirm or refute a direct correlation.
14 Most cats with oral SCC (85%) are examined due to issues related to their oral health. Routine physical examinations identify 15% of all oral SCCs. 12 Many cats are examined for a decrease in appetite, weight loss, or inadequate grooming. Concerns of oral health may include ptyalism and halitosis. Upon physical examination, SCC often appears as an ulcerated area with little or no proliferation ( Figure 1A and B). Alternatively, it may appear as small, round, and fleshy. The neoplasia is commonly more invasive than it appears grossly, and lingual or sublingual SCC can be confused with a linear foreign body. Tooth mobility due to SCC can be mistaken for periodontal disease. Differential diagnoses include other neoplastic lesions (both benign and malignant), infection, inflammatory lesions, and periodontal disease. Incisional (or excisional) biopsy with histopathology is the definitive method to diagnose feline oral SCC.
The extent and degree of bone involvement can be determined with dental radiographs ( Figure 1C) . CT, MRI, or PET/ CT with fluorodeoxyglucose have been shown to be very effective at delineating the tumor margins. 17 Aspiration of mandibular lymph nodes is indicated to stage the disease.
Complete cures are uncommon when treating feline SCC. When the tumor is small, surgical resection is a viable option. Unfortunately, most cases are advanced when presented, making excision less likely. Recurrence rates after mandibulectomy range from 38% 18 to 80%. 19 Three cases of recurrence occurred despite histopathologically clean borders. 18 In addition to high recurrence rates, 1 retrospective study found that 12% of cats never regained the ability to eat or drink after mandibulectomy. 18 Similar to other treatments, radiation therapy alone yields mixed results. One study of 9 cats reported that 5 had a complete response, with a median survival time of 298 days. On the other hand, 4 cats had a partial response, with a median survival time of 60 days. 20 It is thought that feline oral SCC often contains isolated cells that are refractory to radiation therapy and larger populations that are radiosensitive.
14 After radiation therapy (RT), smaller, radioresistant cells may quickly repopulate the area. Shorter radiation dose delivery time (accelerated protocol) may overcome oral SCC's early repopulation capabilities. 20, 21 The accelerated protocol delivers the total treatment in a shorter period of time and sometimes in a larger number of fractions (hyperfractionation). 22 Accelerated protocols have proven beneficial for local control of advanced head and neck SCC in humans. [23] [24] [25] The addition of a chemotherapeutic agent that causes the increased radiosensitivity of neoplastic cells has also been demonstrated to be beneficial. 26 A recent study of 5 cats and 3 dogs with oral SCC that were treated with carboplatin as a radiosensitizing agent and an accelerated protocol demonstrated promising results. 22 Curative intent excisional surgery followed by RT 2 weeks later currently yields the best results in treating feline oral SCC. One study reported that 85% of cats (6 of 7) had a median recurrence time of 12.5 months. 15 Chemotherapy alone, or in conjunction with surgery or radiation therapy, has also shown little benefit. However, recently, a multimodal therapy protocol 27 used on 6 cats reported promising results. Human SCC exhibits cyclooxygenase (COX) to catalyze the synthesis of prostaglandins that are associated with many of the ill effects of the neoplasia. 28, 29 Although it seems that feline SCC does not express COX to the same degree as human SCC, 30 it is thought that some degree of COX inhibition may be beneficial.
14 At least 1 study showed positive results with the in vitro use of the COX inhibitor, piroxicam, and the tyrosine kinase inhibitor, masitinib. In combination, these 2 drugs significantly inhibit tumor cell proliferation. 11 Due to the potential toxicities associated with NSAIDs and tyrosine kinase inhibitors, SCC-associated inflammation, and decreased appetite, corticosteroids may be used instead of NSAIDS. Corticosteroids may have less severe adverse effects in comparison with NSAIDS and kinase inhibitors. Corticosteroids may be appetite stimulating in some cats.
14 The long-term metastasis rate of oral SCC in cats has not been well documented, due to difficulties in controlling local disease. 31 Canine Oral SCC Canine SCC was the most common oral neoplasia in dogs reported by this study (7%, n ¼ 28). Other studies reported similar findings. 32 Most studies reported that canine MM was the next most common oral neoplasia. [33] [34] [35] [36] Oral SCC is an invasive epithelial neoplasia ( Figure 2 ) and is often divided into 2 categories in dogs: tonsillar and nontonsillar. The risk of metastasis is site dependent, with tonsillar and caudal SCC of the tongue carrying a greater risk of metastasis than rostral SCC. Squamous cell carcinoma of the tonsils and base of the tongue has a reported metastasis rate of up to 73%, with local and regional recurrence also being common. [37] [38] [39] The metastatic rate of rostral canine oral SCC is approximately 20%. 40 Squamous cell carcinoma is most commonly reported in the tonsils and gingiva. 33, 41 One study of 21 dogs 42 with nontonsillar SCC reported a 1-year survival rate of 93.5% with curative intent surgery alone. In that same study, the survival rate of dogs not treated was 0%. 42 Curative intent surgery has shown to have a 10% recurrence rate and median survival times in the range of 19 to 26 months. 43 Oral SCC in dogs is considered a radiation-responsive tumor and should be consider as part of the treatment. 44 Age, local tumor recurrence, and location have been reported 45 to be prognostic indicators when treating with radiation. For dogs younger than 6 years receiving radiation therapy for nontonsillar rostral SCC, the median survival time has been reported 45 as 39 months, compared to 9.8 months for those over 6 years of age. Another study reported a disease-free interval and diseasefree survival time for dogs younger than 9 years between 470 and 1080 days, respectively; for dogs older than 9 years, the disease-free interval was 210 days and the disease-free incidence was 315 days. 46 Local recurrence decreased median survival time to 7.1 months, compared to 28.8 months for tumors without local recurrence. 46 Radiation-treated rostral tumors exhibited a 28.1-month survival rate, compared to a 10-month survival rate for caudal tumors. Oral SCC that extended from rostral to caudal had a survival rate of 1.7 months when treated with radiation therapy. 46 For clients who decline surgery and RT for their dogs, chemotherapy is typically reserved to minimize likelihood of metastatic disease. However, the effectiveness of using chemotherapy alone is currently unknown. When used alone, piroxicam produced a 17% response rate with a median survival time of 180 days, compared to 102 days in dogs with stable disease. 47 Slightly better results were observed when piroxicam was used with either cisplatin or carboplatin. This combination yielded a 57% response rate and a median survival time of 272 days, compared to 116 days for the controls. 48 Unfortunately, the combined use of piroxicam with cisplatin and carboplatin is limited, due to a 41% renal toxicity rate.
The median survival time for radiation therapy alone in canines has been reported as 15 to 16 months. When RT is combined with surgery, median survival time increases to 34 months. 45, 46 Because they are often larger and more advanced when diagnosed, lingual and tonsillar SCCs pose a greater surgical challenge to achieve a favorable prognosis and are more likely to metastasize, likely due to denser vascular and lymphatic drainage.
Canine Oral FS
Oral FSs are mesenchymal tumors that are locally invasive and tend to recur after conservative surgical excision (Figure 3 ). 49 A retrospective study of 65 cases 50 of oral FS reported that masses on the maxilla had a median survival time of 488 days, mandibular tumors 301 days, and palatal tumors 40 days. Histologically low-grade, biologically high-grade oral FS is a distinct entity that exhibits the histopathologic characteristics of benign fibrous connective tissue; however, biologically it is very aggressive. Low-grade, biologically high-grade caused bone lysis in 72.7% of cases, 12% of cases developed pulmonary metastasis, and 20% developed metastasis to the regional lymph nodes. 51 Low-grade, biologically high-grade FS has been reported to be most prevalent in golden retrievers. 40 Oral FS is considered to be radiation resistant, and in 1 study of 17 dogs with oral FS, the median survival time was 7 months. To be effective, high doses of radiation (above 50 Gy) must be used. 52, 53 Another study reported that the median progression free survival (PFS) for curative-intent radiation therapy was 417 days, while palliative-intent radiation therapy yielded a 172-day PFS. 50 Patients receiving no RT had a 97-day PFS.
Tumor size has been proven to affect the success of RT. 44 Tumors smaller than 2 cm typically show a PFS of 45 months, compared to tumors less than 4 cm, which have a PFS of 31 months. On the contrary, masses greater than 4 cm reported a PFS of 7 months. 44 The prognosis for surgically resected oral FS showed a median survival time of 22 months in 1 study. 54 Completeness of margins was the most significant factor in median survival time. Surgical removal is the most common form of treatment for oral FS. Following a mandibulectomy, a 59% recurrence rate and a 50% 1-year survival time were reported. 43 Following a maxillectomy, a 40% recurrence rate and a 50% survival rate were observed. 55 The combination of surgery and RT has shown the greatest efficacy in treating oral FS. One study 50 reported a 505-day median survival time and a 301-day median PFS compared to a 220-day median survival time and a medial PFS of 138 days for patients who did not receive combination therapy. Studies substantiating chemotherapy's effectiveness against oral FS are lacking; however, chemotherapy may be important in combination with other therapies. In a study of 4 patients, doxorubicin did not significantly alter median survival time or PFS. 50 The prognosis for FS is guarded, due to the local aggressiveness of the tumor. The combined use of curative-intent surgery and radiation therapy typically yields the best results. 50, 56 Canine MM Several studies have reported MM as the first 33, 57 or the second most common 41 oral tumors in dogs. Males, 33,41,57 cocker spaniels, and dogs with heavily pigmented mucosa 41 are predisposed to developing oral MM. Malignant melanoma is most commonly found on the gingiva; however, it can be found on the lips, tongue, and palate. 33, 58, 59 Grossly, the typical appearance is a grayish or brownish-black firm to friable, ulcerated mass. 57 The combination of surgery and radiation therapy can often provide good local control of the tumor; however, metastatic disease to the lungs is the most common cause of death, ranging from 14% to 67%. 43, 60 A postmortem study of 43 dogs diagnosed with oral MM reported a metastasis rate of 74% in the regional lymph nodes and 65% in the lungs. 41 The medial survival times of dogs with stage II tumors (2-4 cm in diameter, without metastasis) treated with surgery is approximately 6 months. 61, 62 Dogs with metastasis at the time of diagnosis have a significantly shorter median survival time (131 days) and PFS (187 days) than patients without metastasis (567 days and 818 days, respectively) at the time of diagnosis. 63 A better prognosis is seen with histologically well-differentiated melanocytic neoplasms. A study of 64 dogs reported a 23.4-month median survival time and a median survival rate of 34 months following surgical excision. 64 Oral MM is considered to be RT responsive and may be considered as primary treatment. 44, 61, 65, 66 Aggressive and wide surgical resection is the most common and most effective means of controlling the primary tumor. 67, 68 The data reported for the efficacy of chemotherapy used to treat MM are ambiguous, with response rates that tend to be less than 30%. 69, 70 A recent study indicated that the use of adjuvant carboplatin failed to extend survival time. 71 A xenogeneic DNA vaccine a is available for the treatment of MM. A study of 58 dogs receiving the initial series of 4 intradermal injections and a booster 6 months later, if alive, reported no systemic effects and mild local effects. 72 The effectiveness of the melanoma vaccine extending survival times is equivocal. 41, [72] [73] [74] Generally, the prognosis for oral MM is guarded at best. Most consider surgical resection with wide margins as the standard of care. 75 RT is also a valid treatment modality. The melanoma vaccine appears to be safe and may be considered as an adjunctive therapy.
Canine Oral Osteosarcoma
Oral osteosarcoma (OS) often manifests as a soft, readily bleeding, red, fleshy mass with adjacent bone lysis (Figure 4) . Oral osteosarcoma is a mesenchymal cancer associated with malignant osteoblasts that may produce osteoid. 63 Many sources have reported that OS accounts for up to 10% of oral tumors and 12% of total OS. 76 This study reported that 4% of all histopathology results were OS. Oral OS does not seem to be as aggressive as axial or appendicular OS. 77, 78 Maxillofacial OS in dogs is generally regarded as a subgroup of axial or flat bone OS [79] [80] [81] and occurs most frequently in large breeds of dogs, 67, 78 with most weighing over 20 kg. 68, 82 Maxillofacial OS appears to have less metastatic potential than appendicular OS. However, a recent study of 50 dogs with mandibular OS reported a metastatic rate of 58%. 82 The median survival time of these dogs was 525 days.
It has also been reported that 50% of mandibular OS and 90% of maxillary OS show evidence of local recurrence when treated surgically, with or without adjunctive therapies. 77 When metastasis occurs, it primarily spreads via the hematogenous route to the lungs 83 and rarely metastasizes via the lymphatic system. 84 Tumor location has been shown to affect median survival time. 82 Rostral tumors have been reported to have a 30-month median survival time, whereas central tumors and caudal tumors demonstrated an 8-and 5-month median survival time, respectively.
67
Due to challenges in obtaining wide surgical margins, caudal tumors may carry a worse prognosis. The exact etiology of OS is unknown; however, several possible causes have been reported. Ionizing radiation, [84] [85] [86] genetics, 87, 88 preexisting bone disease, 80,89 trauma, 76,89 bone viruses, 76, 89 and metallic bone implants [90] [91] [92] [93] have all been implicated in OS. A presumptive diagnosis can be made based upon radiographic and clinical signs, while histopathology is necessary to make a definitive diagnosis. 76 CT is the preferred imaging modality for both the primary tumor site and for assessment of pulmonary metastasis. 80, 89 To date, no studies exist that report outcomes for dogs with oral and maxillofacial OS treated with RT compared to surgical treatment. 77 Treatment of axial OS in dogs with both curativeintent and palliative RT has reported an increase in median survival times. 81, 94 RT is warranted when other treatment options are not available. Two studies reported that most dogs die as a result of local recurrence with no reported metastasis. 81, 95 Local tumor control is the most challenging problem when dealing with oral OS, and clean margins are imperative in attempting to reduce recurrence. 31 A study of 60 dogs with OS of the skull, including the maxilla and mandible, reported a disease-free interval and survival time of greater than 1503 days with complete excision, compared to a 128-day disease-free interval and a median survival time of 199 days with incomplete incision. 96 It is recommended that oral OS be surgically resected with wide margins for local control. 43, 78, 97 Many chemotherapy agents have been used to treat OS when incomplete tumor resection has been suspected or documented. 77, 81, 82 The results of the studies using chemotherapeutic agents in axial OS are equivocal. 81, 98 Data comparing the success of aggressive surgical resection alone versus various combination of chemotherapy with surgery and/or RT are unclear. 99 The results of studies on the effectiveness of adjunctive therapies for treating oral OS are equivocal, and more studies are needed in these areas. 77 The most important treatment modality is aggressive surgical resection with wide margins, even though the prognosis still remains guarded. 77, 97 Canine POF Peripheral odontogenic fibroma is a benign, slow-growing, noninvasive mesenchymal tumor that was formerly known as fibromatous or ossifying epulis ( Figure 5A) . 100, 101 It is the most common benign tumor of the oral cavity and is thought to arise from the gingiva or periosteum. Dental radiographs may show mineralization (osseous metaplasia) within the center of the mass in the absence of lysis of adjacent bone ( Figure 5B ). It has not been observed to originate within or infiltrate along the periodontal ligament. An analysis of 47 POFs reported that the tumor is most commonly located at the rostral maxilla (47%) and the caudal mandible (21%). 102 The maxillary to mandibular lesion ratio was reported as 1.7:1.
103
Following surgical excision or RT, the prognosis is excellent. The recurrence rate has been reported as 0% to 17% following excision, with or without bone. 103, 104 The osseous metaplasia that POF sometimes exhibits bears no effect on prognosis or treatment plan. Surgical extraction must be done all the way to the underlying periosteum and is the treatment of choice. Broad-based lesions may require en bloc excision, including bone and teeth. Alternatively, smaller recurrent lesions can be simply debulked yearly at the time of routine periodontal therapy.
RT is effective, with a 3-year PFS of 86%. 44 Full-course RT is usually not required because of the high success rate of simple surgical resection. 105 Ultimately, POF is a noninvasive tumor that carries an excellent prognosis following surgical excision.
Canine Acanthomatous Ameloblastoma
Canine acanthomatous ameloblastoma, formerly known as acanthomatous epulis and peripheral ameloblastoma, 102 is the second most common odontogenic tumor of dogs. Canine acanthomatous ameloblastoma has been reported to occur more frequently at the rostral mandible and is a benign (does not metastasize) but highly invasive lesion. 103 For every 1 maxillary CAA, there were 2.3 mandibular CAAs, suggesting a predilection for the mandible. 103 Surgical excision with wide margins is generally considered curative. The local recurrence rate following curative-intent surgical excision is less than 5%. 34, 36, 102, 105 Canine acanthomatous ameloblastoma is formed from the remnants of the dental lamina that reside within the gingiva or bone (rests of Serres) in the tooth-bearing area of the jaws. 102, 106 Most CAA arises from within the gingiva, but the origin may also be intraosseous and expand from the bone. 104 Radiographically, the lesion exhibits bone invasion, tooth displacement, and alveolar bone resorption. 102, 107 Grossly, CAA appears as an exophytic gingival mass with a verrucous surface.
Due to the local aggressiveness and bone-invading tendencies of CAA, curative-intent en bloc surgical excision with 10 mm of normally appearing tissue margin is the treatment of choice. 107 An en bloc excision with at least 10 mm of surrounding normal tissue requires a partial mandibulectomy or maxillectomy. 107 Alternatively, intralesional bleomycin RT has been demonstrated to be an effective treatment modality, with a 3-year PFS of 80% 44 and an overall local recurrence rate of 8% to 18%. 109 Larger tumors (greater than 4 cm) had a worse prognosis, with a likelihood of recurrence of more than 8 times that of smaller tumors. 109 Complications of RT include bone necrosis in 6% of dogs and malignant transformation in 5% to 18% of tumors. 109 
Conclusion
This article assessed the prevalence of the common oral neoplasia reported in a private dentistry practice and compared complimentary studies. Approximately half of all feline samples and nearly one-third of all canine samples were inflammatory, emphasizing the importance of an incisional biopsy to determine appropriate definitive treatment. 
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research and/or authorship of this article. 
